Skip to main content

Methylene Blue

Methylene blue is a visible blue dye and an active drug. The US PROVAYBLUE indication is acquired methemoglobinemia in adults and children; fistula localization, urinary leak testing and other surgical dye uses are off-label. Its redox and monoamine-oxidase effects mean that dye use still requires medication and contraindication review.[1]

Formulation and pharmacology​

PROVAYBLUE contains 5 mg/mL; other products may have different concentrations. Verify the actual vial rather than assuming every injectable product is 1% (10 mg/mL). Methylene blue appears in urine, although urinary color and the timing of efflux can vary. Its visible-light role differs from fluorescence imaging with a compatible camera; an ICG-oriented NIR system is not automatically suitable.[1][2]

Surgical applications​

Fistula localization​

Dilute intravesical methylene blue can help identify communication between the bladder and vagina. In a double-dye examination, oral phenazopyridine colors upper-tract urine orange while the bladder contains blue solution. Blue vaginal staining supports a bladder communication; orange leakage without blue suggests a ureteral source. Mixed colors, urethral leakage, contamination, intermittent leakage and inadequate filling can complicate interpretation. Swab position alone does not define the entire anatomy, and a negative test does not exclude a fistula. Follow the clinical fistula evaluation pathway and obtain anatomical confirmation as indicated.

Urinary anastomosis and bladder leak testing​

Gentle filling with saline or a locally specified dilute dye can identify visible extravasation. Select volume and pressure for the repair; a universal 200–300 mL fill is inappropriate for every reconstructed bladder or urethra. Neither a negative leak test nor a visible ureteral jet excludes later ischemic failure.

Ureteral visualization​

IV methylene blue has been studied as an off-label aid, including fluorescence imaging in digestive surgery. The WSES guideline describes limited clinical evidence; use depends on the intended imaging method, patient safety and local protocol.[2] Concentrated intravesical dye can obscure the field and is not a universal way to “darken the mucosa” to find orifices. Do not use an unverified intraventricular or intrathecal dye technique.

Labeled methemoglobinemia treatment​

For PROVAYBLUE, the usual label regimen is 1 mg/kg IV over 5–30 minutes. One additional 1 mg/kg dose may be given after one hour if methemoglobin remains above 30% or symptoms persist. Persistent disease after two doses requires an alternative approach and expert toxicology/hematology support. For eGFR 15–59 mL/min/1.73 m², the label recommends a single 1 mg/kg dose; do not automatically repeat. If dilution is needed, use the label's 5% dextrose instructions; sodium chloride can reduce solubility. These IV treatment instructions are separate from off-label bladder instillation protocols.[1]

Contraindications and important precautions​

  • G6PD deficiency is a contraindication, as are severe hypersensitivity reactions to methylene blue or another thiazine dye. Do not portray an unvalidated low-dose dye regimen as an established exception.
  • Boxed warning: serotonin syndrome, potentially fatal, with serotonergic drugs and opioids. Review SSRIs, SNRIs, MAO inhibitors and other interacting drugs with anesthesia/pharmacy. Avoid concomitant use; urgent unavoidable treatment requires the label's monitoring precautions. The label advises avoiding serotonergic drugs for 72 hours after the last dose. Do not assume local instillation or a small dose is interaction-free.
  • Hemolysis may occur, sometimes delayed; efficacy can also be limited in some causes of methemoglobinemia.
  • Pregnancy requires an individualized benefit/risk assessment; the label includes pediatric treatment rather than a universal “never IV in neonates” rule. Breastfeeding interruption for up to 8 days is advised after treatment.
  • Renal impairment increases exposure, and hepatic impairment may prolong toxicity and interaction risk.[1]

Monitoring and practical points​

Methylene blue may cause an artifactual decrease, not increase, in pulse-oximeter saturation. Inform anesthesia, assess for true hypoxemia and use an appropriate alternative measurement when needed. Do not dismiss a low reading solely because dye was given. Urine color and some laboratory assays can also be affected. Record the product, dose, concentration and route; use a reviewed local dilution protocol for surgical applications.[1]

See Also​

References​

1. PROVAYBLUE. US prescribing information, revised February 2024. DailyMed.

2. de'Angelis N, Schena CA, Marchegiani F, et al. 2023 WSES guidelines for prevention, detection and management of iatrogenic urinary tract injuries during emergency digestive surgery. World J Emerg Surg. 2023;18:45. doi:10.1186/s13017-023-00513-8.